Citations

Showing 10 of 108135 citations.

Risk Factors of Mortality for Patients Receiving Venovenous Extracorporeal Membrane Oxygenation for COVID-19 Acute Respiratory Distress Syndrome
Bergman, Zachary , Wothe, Jillian K. , Alwan, Fatima, Lofrano, Arianna E., Tointon, Kelly M., Doucette, Melissa, Bohman, J. Kyle , Saavedra-Romero, Ramiro , Lusczek, Elizabeth R. , Brunsvold, Melissa E. , Bergman, Zachary R , Bohman, John K , Brunsvold, Melissa E , Prekker, Matthew E , Beilman, Gregory J.

Mayo Clinic

Surgical Infections | September 8, 2021 | Volume: 22 | Issue: 10 | Pages: 1086-1092

10.1089/sur.2021.114 | PMID 34494893 Get It

Impact of the AACC Global Laboratory Quality Initiative in Partnership with Professional Societies and Universities in Latin America and the Caribbean
Luzzi, Verónica, Colón-Franco, Jessica M , Goldsmith, Barbara, Jara-Aguirre, José, Laterza, Omar, Leung‐Pineda, Van , Palavecino, Elizabeth , Parnas, M. Laura , Zabaleta, Eugenio H, Sierra-Amor, Rosa Isabel, Calderón, Boris , Algeciras‐Schimnich, Alicia , Garcia, Juan D, Jara-Aguirre, Jose C.

Mayo Clinic

The Journal of Applied Laboratory Medicine | September 8, 2021 | Volume: 7 | Issue: 2 | Pages: 596-606

10.1093/jalm/jfab111 | PMID 34910147 Get It

Abstract The Global Lab Quality Initiative (GLQI), formerly known as the Emerging Countries program, was funded through a generous endowment from the Wallace H. Coulter Foundation. The aims of GLQI are to develop and implement innovative programs to promote education and training in laboratory medicine for low- or lower middle-income countries worldwide. From its inception in 2010, the GLQI was focused solely on the Latin America and Caribbean (LAC) region under the purview of AACC’s Latin American Working Group (LAWG), the members of which have strong ties to the region thereby facilitating the partnerships with national societies. The LAWG has provided in-person workshops in the LAC countries, at the AACC Annual Scientific Meeting, and on-demand webinars. The LAWG aims to implement the GLQI aims in the LAC region. In-person workshops are based on best-practice recommendations and sources such as Clinical Laboratory Standard Institute guidelines and supplemented with professional experiences of the LAWG’s lecturers and local experts of the countries visited. In 2015, the GLQI expanded to other regions of the world. Here we report the experience of the LAWG workshops, results of participant surveys, in-person visits to laboratories post-workshop, and the lessons learned throughout the years across different geographic areas. We are hopeful this report provides insights into the challenges and successes of the LAWG in LAC to help support the expansion of the GLQI.
Clinical and Infection Prevention Applications of Severe Acute Respiratory Syndrome Coronavirus 2 Genotyping: An Infectious Diseases Society of America/American Society for Microbiology Consensus Review Document
Greninger, Alexander L. , Bard, Jennifer Dien , Colgrove, Robert C. , Hayden, Mary K. , Humphries, Romney M. , Lowe, Christopher F. , Pillai, Dylan R. , Rhoads, Daniel D. , Yao, Joseph D. , Lee, Francesca M, Graf, Erin H. , Humphries, Romney , Rhoads, Daniel D , Greninger, Alexander L , Hanson, Kimberly E. , Miller, Melissa B.

Mayo Clinic

Clinical Infectious Diseases | September 8, 2021 | Volume: 74 | Issue: 8 | Pages: 1496-1502

10.1093/cid/ciab761 | PMID 34731234 Get It

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged into a world of maturing pathogen genomics, with >2 million genomes sequenced at this writing. The rise of more transmissible variants of concern that affect vaccine and therapeutic effectiveness has led to widespread interest in SARS-CoV-2 evolution. Clinicians are also eager to take advantage of the information provided by SARS-CoV-2 genotyping beyond surveillance purposes. Here, we review the potential role of SARS-CoV-2 genotyping in clinical care. The review covers clinical use cases for SARS-CoV-2 genotyping, methods of SARS-CoV-2 genotyping, assay validation and regulatory requirements, clinical reporting for laboratories, and emerging issues in clinical SARS-CoV-2 sequencing. While clinical uses of SARS-CoV-2 genotyping are currently limited, rapid technological change along with a growing ability to interpret variants in real time foretell a growing role for SARS-CoV-2 genotyping in clinical care as continuing data emerge on vaccine and therapeutic efficacy.
CABANA: underpowered and with detrimental protocol changes: is ‘ablation salvation’?—Reply by the authors of the CABANA trial
Packer, Douglas L. , Lee, Kerry L. , Mark, Daniel B.

Mayo Clinic

EP Europace | September 8, 2021 | Volume: 24 | Issue: 1 | Pages: 3-3

10.1093/europace/euab237 | PMID 34792125 Get It

Centre volume impact on graft survival and waiting list time in donation after circulatory death liver transplantation in the USA
Giorgakis, Emmanouil , Khorsandi, Shirin Elizabeth , Burdine, Lyle , Singer, Andrew L., Hewitt, Winston R. , Heaton, Nigel, Mathur, Amit K. , Khorsandi, Shirin E , Singer, Andrew, Hewitt, Winston, Giorgakis, Emmanouil

Mayo Clinic

British Journal of Surgery | September 8, 2021 | Volume: 108 | Issue: 12 | Pages: e404-e406

10.1093/bjs/znab348 | PMID 34672324 Get It

During 2001–2015, numbers of donation after circulatory death (DCD) liver transplantations (LTs) remained surprisingly low. Post-transplant outcomes improved overall over time, regardless of centre volume. High-volume centres that promoted DCD LT significantly shortened their waiting list time, therefore limiting waiting list mortality and drop-outs.
Insulin-Like Growth Factor 1 in the Early Postoperative Assessment of Acromegaly
Donegan, Diane , Ashrafzadeh‐Kian, Susan , Erickson, Dana , Ashrafzadeh-Kian, Susan, Algeciras‐Schimnich, Alicia

Mayo Clinic

American Journal of Clinical Pathology | September 8, 2021 | Volume: 157 | Issue: 4 | Pages: 595-601

10.1093/ajcp/aqab168 | PMID 34665848 Get It

Abstract Objectives Assessment of surgical outcome in acromegaly is typically recommended at 3 to 6 months following surgery. The purpose of this study was to determine if insulin-like growth factor 1 (IGF-1) concentrations at 6 weeks were equally predictive of surgical outcomes compared with IGF-1 concentrations at 3 to 6 months postoperatively applying newer IGF-1 assays. Methods Retrospective review of patients with newly diagnosed acromegaly who had surgery between 2013 and 2020 and had postoperative IGF-1 measured by 6 weeks and 3 to 6 months. Results At 6 weeks, 20 (35%) of the total 57 had normal IGF-1 and became abnormal in 1 at 3 to 6 months, whereas 37 (65%) of 57 had abnormal IGF-1 concentrations at 6 weeks, which normalized in 1 patient by 3 to 6 months. In patients who changed clinical status, IGF-1 at 6 weeks was within ±0.1-fold of normal. Although a difference was seen between median IGF-1 concentrations (286 vs 267 ng/mL, P = .009) at 6 weeks and 3 to 6 months, the mean reduction was small (–19.9 ng/mL). Conclusions Compared with 3 to 6 months, use of IGF-1 at 6 weeks was associated with a change in clinical status in 3.5% of patients. Therefore, in most patients, IGF-1 at 6 weeks can be used to assess clinical outcome via newer assays.
Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials
Yin, Jun , Salem, Mohamed E. , Dixon, Jesse G. , Jin, Zhaohui , Cohen, Romain , DeGramont, Aimery, Taı̈eb, Julien , Alberts, Steven R. , Schmoll, Hans‐Joachim , George, Thomas J. , Goldberg, Richard M. , Lonardi, Sara , Shi, Qian , Taieb, Julien , Alberts, Steven R , George, Thomas J , Goldberg, Richard M , Kerr, Rachel , Lonardi, Sara , Yothers, Greg , André, Thierry , Shi, Qian , Schmoll, Hans-Joachim , Jin, Zhaohui , Cohen, Romain , Dixon, Jesse G , Gramont, Aimery de , Cutsem, Eric Van , Wolmark, Norman , Saltz, Leonard B. , Kerr, Rachel , Yoshino, Takayuki , Yothers, Greg , Grothey, Axel , André, Thierry

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 8, 2021 | Volume: 114 | Issue: 1 | Pages: 60-67

10.1093/jnci/djab187 | PMID 34505880 Get It

Abstract Background Disease-free survival (DFS) with a 3-year median follow-up (3-year DFS) was validated as a surrogate for overall survival (OS) with a 5-year median follow-up (5-year OS) in adjuvant chemotherapy colon cancer (CC) trials. Recent data show further improvements in OS and survival after recurrence in patients who received adjuvant FOLFOX. Hence, reevaluation of the association between DFS and OS and determination of the optimal follow-up duration of OS to aid its utility in future adjuvant trials are needed. Methods Individual patient data from 9 randomized studies conducted between 1998 and 2009 were included; 3 trials tested biologics. Trial-level surrogacy examining the correlation of treatment effect estimates of 3-year DFS with 5 to 6.5-year OS was evaluated using both linear regression (RWLS2) and Copula bivariate (RCopula2) models and reported with 95% confidence intervals (CIs). For R2, a value closer to 1 indicates a stronger correlation. Results Data from a total of 18 396 patients were analyzed (median age = 59 years; 54.0% male), with 54.1% having low-risk tumors (T1-3 and N1), 31.6% KRAS mutated, 12.3% BRAF mutated, and 12.4% microsatellite instability high or deficient mismatch repair tumors. Trial-level correlation between 3-year DFS and 5-year OS remained strong (RWLS2 = 0.82, 95% CI = 0.67 to 0.98; RCopula2 = 0.92, 95% CI = 0.83 to 1.00) and increased as the median follow-up of OS extended. Analyses limited to trials that tested biologics showed consistent results. Conclusions Three-year DFS remains a validated surrogate endpoint for 5-year OS in adjuvant CC trials. The correlation was likely strengthened with 6 years of follow-up for OS.
Implications of the NADase CD38 in COVID pathophysiology
Zeidler, Julianna D. , Kashyap, Sonu , Hogan, Kelly A. , Chini, Eduardo N. , Chini, Eduardo Nunes

Mayo Clinic

Physiological Reviews | September 8, 2021 | Volume: 102 | Issue: 1 | Pages: 339-341

10.1152/physrev.00007.2021 | PMID 34494892 Get It

During the COVID-19 pandemic, efforts have been made worldwide to develop effective therapies to address the devastating immune-mediated effects of SARS-CoV-2. With the exception of monoclonal antibody-mediated therapeutics and preventive approaches such as mass immunization, most experimental or repurposed drugs have failed in large randomized clinical trials ( https://www.who.int/publications/i/item/therapeutics-and-covid-19-living-guideline ). The worldwide spread of SARS-CoV-2 virus revealed specific susceptibilities to the virus among the elderly and individuals with age-related syndromes. These populations were more likely to experience a hyperimmune response characterized by a treatment-resistant acute lung pathology accompanied by multiple organ failure. These observations underscore the interplay between the virus, the biology of aging, and outcomes observed in the most severe cases of SARS-CoV-2 infection. The ectoenzyme CD38 has been implicated in the process of “inflammaging” in aged tissues. In a current publication, Horenstein et al. present evidence to support the hypothesis that CD38 plays a central role in altered immunometabolism resulting from COVID-19 infection. The authors discuss a critical but underappreciated trifecta of CD38-mediated NAD + metabolism, aging, and COVID-19 immune response and speculate that the CD38/NAD + axis is a promising therapeutic target for this disease.
Co-Ordination of Mucosal B Cell and CD8 T Cell Memory by Tissue-Resident CD4 Helper T Cells
Son, Young Min , Son, Y M , Sun, Jie

Mayo Clinic

Cells | September 8, 2021 | Volume: 10 | Issue: 9 | Pages: 2355

10.3390/cells10092355 | PMID 34572004 Get It

Adaptive cellular immunity plays a major role in clearing microbial invasion of mucosal tissues in mammals. Following the clearance of primary pathogens, memory lymphocytes are established both systemically and locally at pathogen entry sites. Recently, resident memory CD8 T and B cells (TRM and BRM respectively), which are parked mainly in non-lymphoid mucosal tissues, were characterized and demonstrated to be essential for protection against secondary microbial invasion. Here we reviewed the current understanding of the cellular and molecular cues regulating CD8 TRM and BRM development, maintenance and function. We focused particularly on elucidating the role of a novel tissue-resident helper T (TRH) cell population in assisting TRM and BRM responses in the respiratory mucosa following viral infection. Finally, we argue that the promotion of TRH responses by future mucosal vaccines would be key to the development of successful universal influenza or coronavirus vaccines, providing long-lasting immunity against a broad spectrum of viral strains.
Application of artificial intelligence to the electrocardiogram
Attia, Zachi I. , Harmon, David , Behr, Elijah R. , Friedman, Paul A. , Harmon, David M , Behr, Elijah Raphael , Attia, Zachi I

Mayo Clinic

European Heart Journal | September 8, 2021 | Volume: 42 | Issue: 46 | Pages: 4717-4730

10.1093/eurheartj/ehab649 | PMID 34534279 Get It

Abstract Artificial intelligence (AI) has given the electrocardiogram (ECG) and clinicians reading them super-human diagnostic abilities. Trained without hard-coded rules by finding often subclinical patterns in huge datasets, AI transforms the ECG, a ubiquitous, non-invasive cardiac test that is integrated into practice workflows, into a screening tool and predictor of cardiac and non-cardiac diseases, often in asymptomatic individuals. This review describes the mathematical background behind supervised AI algorithms, and discusses selected AI ECG cardiac screening algorithms including those for the detection of left ventricular dysfunction, episodic atrial fibrillation from a tracing recorded during normal sinus rhythm, and other structural and valvular diseases. The ability to learn from big data sets, without the need to understand the biological mechanism, has created opportunities for detecting non-cardiac diseases as COVID-19 and introduced challenges with regards to data privacy. Like all medical tests, the AI ECG must be carefully vetted and validated in real-world clinical environments. Finally, with mobile form factors that allow acquisition of medical-grade ECGs from smartphones and wearables, the use of AI may enable massive scalability to democratize healthcare.